Clinical-stage biotechnology company BioAge Labs Inc. has announced its financial results for the first quarter of 2026, reporting a GAAP loss per share of $0.52 and revenue of $2.8 million. The performance aligns with the company's previously provided guidance range.
Financial Overview The report indicates a net loss of approximately $21 million for the quarter, widening from a net loss of $18 million in the same period last year. Research and development expenses reached $18 million, a 15% year-over-year increase, primarily driven by the advancement of the Phase 2 clinical trial for its lead drug candidate, BGE-303, for obesity treatment. General and administrative expenses were approximately $6 million, remaining largely consistent with the prior-year period.
As of March 31, the company held cash, cash equivalents, and short-term investments of about $240 million, a decrease of roughly $15 million from the beginning of the year. The company reiterated that its existing capital is sufficient to fund operations into the second half of 2028.
Pipeline Progress The $2.8 million in revenue primarily stemmed from a milestone payment under a collaboration agreement with Takeda Pharmaceutical. Top-line data from the Phase 2 trial for BGE-303 is anticipated in the fourth quarter of 2026. Over 80% of the targeted patient enrollment has been completed, with progress meeting expectations. The company has also initiated preclinical studies for BGE-304 targeting metabolic dysfunction-associated steatohepatitis (MASH), with an Investigational New Drug application expected to be submitted in 2027.
Management Commentary The Chief Executive Officer stated in a release that the Phase 2 trial for BGE-303 is progressing smoothly and the company looks forward to the data. The partnership with Takeda continues to generate non-dilutive funding. The company also confirmed its participation in the upcoming American Diabetes Association Scientific Sessions in Boston next week, where it will provide an update on the clinical development plan for BGE-303.
Market Reaction Following the earnings release, BioAge Labs' stock rose approximately 2% in after-hours trading. Analyst ratings for the stock are distributed as follows: 5 Buy, 2 Hold, and 0 Sell recommendations. The median price target is $65, implying an upside potential of about 40% from current levels. Investor focus is expected to center on the Phase 2 clinical data readout in the fourth quarter.